

B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/BAF72949BD2FEN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: BAF72949BD2FEN

Abstracts

The 7 major B cell chronic lymphocytic leukemia markets are expected to exhibit a CAGR of 4.62% during 2024-2034.

The B cell chronic lymphocytic leukemia market has been comprehensively analyzed in IMARC's new report titled "B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". B cell chronic lymphocytic leukemia (B-CLL) is a type of cancer that primarily affects B cells, which form white blood cells in the body. It is characterized by the presence of mature-appearing lymphocytes that are larger than normal. As a result, the white blood cells do not function properly and accumulate in the blood, lymph nodes, and other tissues. The symptoms of B-CLL can vary from person to person, and a few patients may not experience any indications in the early stages of the ailment. This disease commonly manifests as fatigue, enlarged lymph nodes, recurrent infections, unintentional weight loss, night sweats, easy bruising or bleeding, etc. The diagnosis of the condition involves a combination of clinical evaluation, medical history assessment, and laboratory tests. A complete blood count and peripheral blood smear are also utilized in patients to determine the appearance and characteristics of the blood cells, including the lymphocytes. Numerous imaging studies, like computed tomography (CT) scans and ultrasounds, may be performed to assess the extent of lymph node enlargement, organ involvement, and staging of the disease.

The increasing cases of genetic mutations that can affect the normal functioning of B lymphocytes, thereby leading to uncontrolled growth and accumulation of abnormal cells, are primarily driving the B cell chronic lymphocytic leukemia market. In addition to this, the growing geriatric population, who are more susceptible to the development of

cancer due to a weakened immune response, is also creating a positive outlook for the market. Moreover, the widespread adoption of Bruton's tyrosine kinase inhibitors, such as ibrutinib and acalabrutinib, which block specific proteins responsible for the survival and proliferation of unhealthy cells, is further bolstering the market growth. Apart from this, the escalating application of immunophenotyping technique, since it helps in monitoring the response to regimens and detecting the presence of a small number of leukemia cells that remain after treatment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of chimeric antigen receptor T-cell (CAR-T) therapy, which modifies a patient's own immune cells to recognize and attack tumors, is expected to drive the B cell chronic lymphocytic leukemia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the B cell chronic lymphocytic leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for B cell chronic lymphocytic leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the B cell chronic lymphocytic leukemia market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the B cell chronic lymphocytic leukemia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the B cell chronic lymphocytic leukemia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current B cell chronic lymphocytic leukemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the B cell chronic lymphocytic leukemia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the B cell chronic lymphocytic leukemia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the B cell chronic lymphocytic leukemia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of B cell chronic lymphocytic leukemia across the seven major markets?

What is the number of prevalent cases (2018-2034) of B cell chronic lymphocytic leukemia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of B cell chronic lymphocytic leukemia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with B cell chronic lymphocytic leukemia across the seven major markets?

What is the size of the B cell chronic lymphocytic leukemia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of B cell chronic lymphocytic leukemia?

What will be the growth rate of patients across the seven major markets?

B Cell Chronic Lymphocytic Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for B cell chronic lymphocytic leukemia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the B cell chronic lymphocytic leukemia market?

What are the key regulatory events related to the B cell chronic lymphocytic leukemia market?

What is the structure of clinical trial landscape by status related to the B cell chronic lymphocytic leukemia market?

What is the structure of clinical trial landscape by phase related to the B cell chronic lymphocytic leukemia market?

What is the structure of clinical trial landscape by route of administration related to the B cell chronic lymphocytic leukemia market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - UNMET NEEDS

10 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - KEY ENDPOINTS OF TREATMENT

11 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - MARKETED PRODUCTS

- 11.1 List of B Cell Chronic Lymphocytic Leukemia Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Treanda (Bendamustine) - Astellas Pharma
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results

- 11.1.1.5 Sales Across Major Markets
- 11.1.2 Venclexta (Venetoclax) - AbbVie/Genentech
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Gazyva (Obinutuzumab) - Roche
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Arzerra (Ofatumumab) - Genmab/Novartis
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Zydelig (Idelalisib) - Gilead Sciences
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - PIPELINE DRUGS

12.1 List of B Cell Chronic Lymphocytic Leukemia Pipeline Drugs Across the Top 7 Markets

- 12.1.1 NVG111 - NovalGen
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
- 12.1.2 Epcoritamab - Genmab/AbbVie

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 IOV 2001 - Iovance Biotherapeutics
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 Pirtobrutinib - Loxo Oncology
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 SC291 - Sana Biotechnology
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. B CELL CHRONIC LYMPHOCYTIC LEUKEMIA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 B Cell Chronic Lymphocytic Leukemia - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 B Cell Chronic Lymphocytic Leukemia - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 B Cell Chronic Lymphocytic Leukemia - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 B Cell Chronic Lymphocytic Leukemia - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 B Cell Chronic Lymphocytic Leukemia - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 B Cell Chronic Lymphocytic Leukemia - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 B Cell Chronic Lymphocytic Leukemia - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 B Cell Chronic Lymphocytic Leukemia - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

16 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/BAF72949BD2FEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BAF72949BD2FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

